A Phase I/II, Open-label, Multicenter Study of ACY-1215 administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
ID Number 12-0056Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
ACY-1215 is an experimental new drug that is being developed to see if it is safe and effective against multiple myeloma. The term “experimental” means the study drug being tested has not been approved by the United States Food and Drug Administration (FDA) or other regulatory agencies and is not available for prescription. ACY-1215 is thought to block enzymes that are necessary for rapidly growing cells (like cancer cells) to survive.
The purpose of this study is to test the safety of the study drug ACY-1215. This includes trying to find out how well ACY-1215 is tolerated as well as trying to find out how much of the drug can be given safely to people. In addition, the study will test the amount of drug that gets into the blood, how long it stays in the blood, what the drug does in the body, and whether ACY-1215 works against people’s cancer.
To be able to take part in this study, a person must have multiple myeloma and they are to have received at least 2 prior treatments for their cancer. These people who may be able to take part in this study must also either have not responded to their most recent treatment or had their cancer return after their most recent treatment. In addition, these people who may be able to take part in this study must have had either (1) had a bone marrow transplant already, (2) have no wish to have a transplant, (3) or cannot receive a transplant.
Recruiting Patients: No